sertraline + S,S-reboxetine

A combination of **sertraline**, a selective serotonin reuptake inhibitor (SSRI), and **S,S-reboxetine**, a selective noradrenaline reuptake inhibitor (NRI), used experimentally for treatment-resistant or difficult-to-treat major depressive disorder (MDD). Sertraline increases synaptic serotonin by inhibiting its reuptake, while S,S-reboxetine selectively inhibits noradrenaline reuptake, enhancing its availability. The rationale for combining these drugs is to mimic or enhance the dual-action antidepressant profile (serotonergic and noradrenergic activity), potentially leading to improved efficacy in patients unresponsive to monotherapy.

Other names

sertraline + reboxetine